Larimar Therapeutics (LRMR)

• Market cap: $297M
• 1 day: -0.29%
• 5 days: -10.36%
• 1 month: -26.69%
• 3 months: -5.46%
• 6 months: 59.45%
• Year to date: -13.72%
• 1 year: -62.06%
• 5 years: -82.51%
• 10 years: -97.52%
• Sector: Healthcare
• Industry: Biotechnology

About: Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell-penetrating peptide (CPP) technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia.

Employees: 65